Long Term DAPT Extension Consideration Tool

Long Term Dual Antiplatelet Therapy Extension Consideration Tool Explanation and Clinical Context This tool provides a structured approach to consider extension of dual antiplatelet therapy beyond the first year after an acute coronary syndrome. It is intended for patients who have completed at least several months of dual antiplatelet therapy with aspirin and a P2Y12 inhibitor and who are now being evaluated for continued treatment in the range of one to three years after the index event. It is not a replacement for validated risk scores but translates key messages of the two thousand twenty five acute coronary syndrome guideline into a simple bedside checklist.

The guideline recommends dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor for at least one year as the default strategy in patients with acute coronary syndrome who are not at high bleeding risk. In select patients who have tolerated dual antiplatelet therapy it may be reasonable to extend treatment beyond one year after considering the balance between long term thrombotic risk and bleeding risk. Prolonged dual antiplatelet therapy lowers the risk of late myocardial infarction and stent thrombosis but at the cost of increased major bleeding.

Trials such as DAPT and others have shown this balance, and the guideline underscores the need to individualize duration rather than simply continue therapy for all patients beyond one year. To guide this individualisation the guideline highlights two groups of complementary tools. First are ischemic risk markers such as prior myocardial infarction multivessel coronary disease multiple or complex stents left ventricular dysfunction diabetes chronic kidney disease and prior stent thrombosis.

These factors identify patients with a greater absolute risk of recurrent events who are more likely to benefit from continued antiplatelet intensity. Second are bleeding risk tools including the Academic Research Consortium high bleeding risk criteria and scores such as PRECISE DAPT and DAPT which combine clinical and laboratory data to estimate the risk of major bleeding during prolonged therapy. The Academic Research Consortium definition considers a patient to be at high bleeding risk if at least one major or two minor criteria are present such as advanced age anemia severe chronic kidney disease requirement for oral anticoagulation prior intracranial hemorrhage or recent serious bleeding.

The logic embedded in this tool reflects these principles. It first confirms that the patient has completed at least twelve months after the index event and has tolerated dual antiplatelet therapy without major bleeding. It then counts simple ischemic risk features and bleeding risk features which are surrogates for the more detailed scores referenced in the guideline.

Patients with several ischemic features and none or very few bleeding features fall into a category where extended dual antiplatelet therapy may be reasonable particularly in the first three years after the event when recurrence risk remains elevated. Patients with multiple bleeding features especially those meeting Academic Research Consortium high bleeding risk criteria are usually better served by a shorter duration of dual antiplatelet therapy and early transition to single antiplatelet therapy. The presence of an indication for long term oral anticoagulant therapy such as atrial fibrillation or venous thromboembolism is a special situation addressed separately in the guideline.

In these patients extended triple therapy with aspirin a P2Y12 inhibitor and oral anticoagulant leads to substantial bleeding risk. The recommended strategy is early discontinuation of aspirin and continuation of oral anticoagulant with a single P2Y12 inhibitor usually clopidogrel rather than prolongation of dual antiplatelet therapy. Decisions beyond twelve months are then guided by chronic coronary disease recommendations rather than by acute coronary syndrome specific dual antiplatelet extension.

Clinicians should interpret the output of this tool as supportive information rather than as a directive. Formal application of risk scores such as DAPT and PRECISE DAPT arterial imaging findings patient preference and local practice patterns all influence the final decision. Discussion with the patient should emphasise both potential reduction in recurrent myocardial infarction or stent thrombosis and the increased chance of bleeding including gastrointestinal and intracranial events.

In any situation where there is uncertainty or where the tool suggests extended therapy but bleeding risk is rising the safer course is to shorten dual antiplatelet therapy and optimise other secondary prevention measures such as lipid lowering agents blood pressure control glucose management and lifestyle interventions. Reference Rao SV O Donoghue ML Ruel M et al. two thousand twenty five ACC AHA ACEP NAEMSP SCAI guideline for the management of patients with acute coronary syndromes. Journal of the American College of Cardiology two thousand twenty five volume eighty five pages two one three five to two two three seven.